AI Engines For more Details: Perplexity Kagi Labs You
Digestive Health: Psyllium is known for its beneficial effects on digestive health. As a soluble fiber, it absorbs water in the digestive tract, forming a gel-like substance that softens stools and promotes regular bowel movements. Psyllium can help alleviate constipation by adding bulk to the stool and facilitating its passage through the colon. Additionally, psyllium may help relieve symptoms of diarrhea by absorbing excess water and solidifying loose stools.
Management of Irritable Bowel Syndrome (IBS): Psyllium supplementation may be beneficial for individuals with irritable bowel syndrome (IBS), a common gastrointestinal disorder characterized by abdominal pain, bloating, and changes in bowel habits. Psyllium can help regulate bowel movements and improve stool consistency in individuals with IBS, reducing symptoms such as constipation or diarrhea. Its ability to modulate gut motility and promote regularity may provide relief for some IBS patients.
Blood Glucose Regulation: Psyllium has been shown to have favorable effects on blood glucose levels and insulin sensitivity. As a soluble fiber, it slows down the absorption of carbohydrates in the intestine, leading to a gradual release of glucose into the bloodstream. This helps prevent rapid spikes in blood sugar levels after meals, promoting better glycemic control and reducing the risk of insulin resistance and type 2 diabetes. Psyllium supplementation may be particularly beneficial for individuals with diabetes or prediabetes.
Cholesterol Reduction: Several studies have demonstrated that psyllium supplementation can help lower blood cholesterol levels, especially LDL cholesterol, commonly known as "bad" cholesterol. Psyllium binds to bile acids in the intestine, promoting their excretion in the feces and reducing their reabsorption. This leads to increased bile acid synthesis from cholesterol in the liver, which helps lower circulating cholesterol levels and reduce the risk of cardiovascular disease.
Weight Management: Psyllium supplementation may aid in weight management and obesity prevention by promoting feelings of fullness and reducing appetite. By absorbing water and expanding in the stomach, psyllium creates a sense of satiety, which can help control food intake and reduce calorie consumption. Additionally, psyllium may slow down the digestion and absorption of nutrients, leading to improved weight loss outcomes when combined with a calorie-controlled diet.
Heart Health: In addition to lowering cholesterol levels, psyllium may have other beneficial effects on heart health. It has been associated with improvements in blood pressure and markers of inflammation, both of which are important risk factors for cardiovascular disease. By promoting better lipid profiles, glycemic control, and overall gut health, psyllium may contribute to the prevention of heart disease and stroke.
Colon Health: Psyllium's bulking and water-holding properties may help support colon health by promoting regular bowel movements and preventing constipation. Adequate fiber intake is associated with a reduced risk of colorectal cancer and other gastrointestinal disorders. Psyllium supplementation may also help cleanse the colon and remove toxins and waste products, further supporting overall colon health.
Rank | Probiotic | Impact |
---|---|---|
species | Akkermansia muciniphila | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
Acne | 0.3 | 0.3 | 0 |
ADHD | 0.9 | 3.3 | -2.67 |
Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.6 | -0.2 |
Allergic Rhinitis (Hay Fever) | 0.6 | 0.6 | 0 |
Allergies | 1.7 | 1.6 | 0.06 |
Allergy to milk products | 0.3 | 1.4 | -3.67 |
Alopecia (Hair Loss) | 0.3 | 0.2 | 0.5 |
Alzheimer's disease | 5.2 | 4.2 | 0.24 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.2 | 0.9 | 1.44 |
Ankylosing spondylitis | 2.1 | 1.1 | 0.91 |
Anorexia Nervosa | 3 | 0.3 | 9 |
Antiphospholipid syndrome (APS) | 0.6 | -0.6 | |
Asthma | 2.6 | 1.6 | 0.63 |
Atherosclerosis | 2.4 | 0.8 | 2 |
Atrial fibrillation | 1.7 | 2.8 | -0.65 |
Autism | 7.6 | 6.5 | 0.17 |
Barrett esophagus cancer | 0.8 | 0.6 | 0.33 |
benign prostatic hyperplasia | 0.3 | 0.3 | |
Bipolar Disorder | 2 | 2.3 | -0.15 |
Brain Trauma | 2.7 | 0.8 | 2.38 |
Breast Cancer | 0.6 | -0.6 | |
Carcinoma | 1.4 | 1.4 | 0 |
Celiac Disease | 2.4 | 2.6 | -0.08 |
Cerebral Palsy | 1.7 | 0.6 | 1.83 |
Chronic Fatigue Syndrome | 4.2 | 3.6 | 0.17 |
Chronic Kidney Disease | 1.1 | 1.1 | 0 |
Chronic Lyme | 0.9 | 0.9 | |
Chronic Obstructive Pulmonary Disease (COPD) | 1.9 | 1.5 | 0.27 |
Chronic Urticaria (Hives) | 1.3 | 1.7 | -0.31 |
Coagulation / Micro clot triggering bacteria | 1.4 | 1.4 | |
Colorectal Cancer | 1.3 | 3.7 | -1.85 |
Constipation | 1.2 | 2.3 | -0.92 |
Coronary artery disease | 1.4 | 1.5 | -0.07 |
COVID-19 | 7.1 | 5.3 | 0.34 |
Crohn's Disease | 6.1 | 6.3 | -0.03 |
cystic fibrosis | 2 | 2 | |
deep vein thrombosis | 1 | 1 | |
Depression | 6.9 | 8.2 | -0.19 |
Dermatomyositis | 0.4 | -0.4 | |
Eczema | 1.4 | 2.3 | -0.64 |
Endometriosis | 2.4 | 2 | 0.2 |
Eosinophilic Esophagitis | 0.6 | 0.3 | 1 |
Epilepsy | 1.9 | 2.6 | -0.37 |
erectile dysfunction | 0.5 | 0 | 0 |
Fibromyalgia | 1.7 | 0.6 | 1.83 |
Functional constipation / chronic idiopathic constipation | 1.9 | 4.4 | -1.32 |
gallstone disease (gsd) | 1.6 | 0.8 | 1 |
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1 | -1 | |
Generalized anxiety disorder | 0.4 | 0.8 | -1 |
giant cell arteritis | 0.3 | 0.3 | |
Glioblastoma | 1.5 | 0.6 | 1.5 |
Gout | 0.3 | 0.8 | -1.67 |
Graves' disease | 2.4 | 0.9 | 1.67 |
Halitosis | 0.3 | 1.6 | -4.33 |
Hashimoto's thyroiditis | 1.3 | 1.5 | -0.15 |
Hemorrhoidal disease, Hemorrhoids, Piles | 0.6 | 0.6 | |
Hidradenitis Suppurativa | 0.6 | 0.6 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.2 | 1.5 | -6.5 |
hypercholesterolemia (High Cholesterol) | 1.4 | 0.5 | 1.8 |
hyperglycemia | 1.6 | 1.6 | 0 |
Hyperlipidemia (High Blood Fats) | 0.7 | 0.3 | 1.33 |
hypersomnia | 0.9 | -0.9 | |
hypertension (High Blood Pressure | 4.4 | 2.3 | 0.91 |
Hypothyroidism | 0.9 | 0.8 | 0.13 |
Hypoxia | 0.3 | 1 | -2.33 |
IgA nephropathy (IgAN) | 2.2 | 0.8 | 1.75 |
Inflammatory Bowel Disease | 5 | 4.1 | 0.22 |
Insomnia | 2.7 | 0.4 | 5.75 |
Intelligence | 1.3 | 1.2 | 0.08 |
Intracranial aneurysms | 1.4 | 0.9 | 0.56 |
Irritable Bowel Syndrome | 5.9 | 5 | 0.18 |
Liver Cirrhosis | 4.2 | 4.9 | -0.17 |
Long COVID | 9 | 8 | 0.13 |
Low bone mineral density | 2.5 | 0.7 | 2.57 |
Lung Cancer | 0.5 | 1.4 | -1.8 |
ME/CFS with IBS | 1.4 | 0.3 | 3.67 |
ME/CFS without IBS | 1.4 | 0.2 | 6 |
Menopause | 0.6 | -0.6 | |
Metabolic Syndrome | 7.5 | 5.6 | 0.34 |
Mood Disorders | 9 | 8.8 | 0.02 |
multiple chemical sensitivity [MCS] | 0.4 | 0.6 | -0.5 |
Multiple Sclerosis | 4.4 | 1.3 | 2.38 |
Multiple system atrophy (MSA) | 1.4 | 0.8 | 0.75 |
myasthenia gravis | 0.2 | -0.2 | |
Neuropathy (all types) | 0.8 | 0.6 | 0.33 |
neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.8 | -0.33 |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.6 | 1.8 | 0.44 |
Obesity | 4.3 | 5.1 | -0.19 |
obsessive-compulsive disorder | 2 | 5.3 | -1.65 |
Osteoarthritis | 0.8 | 0.5 | 0.6 |
Osteoporosis | 0.4 | 2.1 | -4.25 |
pancreatic cancer | 0.5 | -0.5 | |
Parkinson's Disease | 6.4 | 1.2 | 4.33 |
Polycystic ovary syndrome | 1 | 0.9 | 0.11 |
Postural orthostatic tachycardia syndrome | 0.7 | -0.7 | |
Premenstrual dysphoric disorder | 0.2 | 0.2 | |
primary biliary cholangitis | 1.1 | 0.5 | 1.2 |
Psoriasis | 1.1 | 3.3 | -2 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.9 | 4.8 | 0.23 |
Rosacea | 0.4 | 0.4 | |
Schizophrenia | 5 | 2.6 | 0.92 |
scoliosis | 0.7 | 0.5 | 0.4 |
sensorineural hearing loss | 0 | 0 | |
Sjögren syndrome | 1.5 | 2 | -0.33 |
Sleep Apnea | 2.5 | 1.1 | 1.27 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.4 | 0.3 | 0.33 |
Stress / posttraumatic stress disorder | 4.1 | 2.2 | 0.86 |
Systemic Lupus Erythematosus | 2.2 | 2.8 | -0.27 |
Tic Disorder | 0.2 | 1.1 | -4.5 |
Tourette syndrome | 1 | 0.3 | 2.33 |
Type 1 Diabetes | 3 | 2.2 | 0.36 |
Type 2 Diabetes | 6 | 5.5 | 0.09 |
Ulcerative colitis | 3.7 | 2.9 | 0.28 |
Unhealthy Ageing | 1.6 | 3 | -0.88 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.